PPAR Agonists as Therapeutics for CNS Trauma and Neurological Diseases
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Traumatic injury or disease of the spinal cord and brain elicits multiple cellular and biochemical reactions that together cause or are associated with neuropathology. Specifically, injury or disease elicits acute infiltration and activation of immune cells, death of neurons and glia, mitochondrial dysfunction, and the secretion of substrates that inhibit axon regeneration. In some diseases, inflammation is chronic or non-resolving. Ligands that target PPARs (peroxisome proliferator-activated receptors), a group of ligand-activated transcription factors, are promising therapeutics for neurologic disease and CNS injury because their activation affects many, if not all, of these interrelated pathologic mechanisms. PPAR activation can simultaneously weaken or reprogram the immune response, stimulate metabolic and mitochondrial function, promote axon growth and induce progenitor cells to differentiate into myelinating oligodendrocytes. PPAR activation has beneficial effects in many pre-clinical models of neurodegenerative diseases and CNS injury; however, the mechanisms through which PPARs exert these effects have yet to be fully elucidated. In this review we discuss current literature supporting the role of PPAR activation as a therapeutic target for treating traumatic injury and degenerative diseases of the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alternative activation of macrophages: mechanism and functions
Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197 · cited 3×
“The ability to reduce inflammation and the different receptor dependency of pioglitazone and rosiglitazone is likely explained by immune cells expressing both PPARγ and PPARδ receptors and each receptor having different thresholds for activation by rosiglitazone (Sakamoto et al., 2000; Gordon and Martinez, 2010).”
BackgroundATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“Chronic persistence of M1 macrophages is thought to exacerbate disease and tissue pathology (Horn et al., 2008; Busch et al., 2009; Kigerl et al., 2009; Martinez et al., 2009; Hu et al., 2012).”
BackgroundKigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130
Self-citationMacrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107 · cited 1×
“In particular, activation of these PPARs in macrophages induces the M2 markers Arg1, CD206, YM1 and FIZZ1; these effects are lost in mice deficient for either receptor (Bouhlel et al., 2007; Odegaard et al., 2007, 2008; Gallardo-Soler et al., 2008; Kang et al., 2008).”
BackgroundRoles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 1×
“PPARs (peroxisome proliferator-activated receptors) comprise a family of ligand-activated transcription factors that play a vital role in cellular processes such as cell differentiation and metabolism (Kersten et al., 2000; Bensinger and Tontonoz, 2008).”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 1×
“Ibuprofen (which activates PPARγ at micromolar levels) inhibits RhoA and stimulates corticospinal and serotonergic axon sprouting after spinal cord transection in rats (Lehmann et al., 1997; Fu et al., 2007).”
BackgroundInfiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool
Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M., & Rossi, F. M. V. (2011) · Nature Neuroscience · doi:10.1038/nn.2887 · Cited by 1,061 · cited 1×
“In EAE, infiltration of monocytes correlates with progression to the severe paralytic stages of disease (Ajami et al., 2011).”
Background
Cited by
Macrophage activation and its role in repair and pathology after spinal cord injury
Gensel, J. C., & Zhang, B. (2015) · Brain Research · doi:10.1016/j.brainres.2014.12.045 · Cited by 771
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 369
Restoring function after spinal cord injury: towards clinical translation of experimental strategies
Ramer, L. M., Ramer, M. S., & Bradbury, E. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70144-9 · Cited by 324
Pearn, M. L., Niesman, I. R., Egawa, J., Sawada, A., Almenar-Queralt, A., Shah, S. B., Duckworth, J. L., & Head, B. P. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0400-1 · Cited by 296
PPARβ/δ: linking metabolism to regeneration
Magadum, A., & Engel, F. B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072013 · Cited by 110
Metadata
- Authors
- Mandrekar-Colucci, S., Sauerbeck, A., Popovich, P. G., & McTigue, D. M.
- Venue
- ASN Neuro
- Publisher
- Informa UK Limited
- Published
- 2013-10
- Volume
- 5
- Issue
- 5
- Pages
- e00129-e00129
- ISSN
- 1759-0914 (ISSN-L)
- OpenAlex
- W2026082154
- Cited by
- 91
- References
- 41
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPAR Agonists as Therapeutics for CNS Trauma and Neurological Diseases. https://app.cochat.ai/papers/10.1042/an20130030
- The paper
- Mandrekar-Colucci, S., Sauerbeck, A., Popovich, P. G., & McTigue, D. M. (2013). PPAR Agonists as Therapeutics for CNS Trauma and Neurological Diseases. ASN Neuro. https://doi.org/10.1042/an20130030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.